Urban Edge Reports Q2 2025 Earnings with Revenue Growth and Pipeline Progress
Urban Edge (UE) reported Q2 2025 earnings with net revenue of $12.5 million, up 45% year-over-year and 44% sequentially. The company also highlighted progress in its pipeline, including the first patient dosed in a Phase II trial for tebapivat in sickle cell disease and an IND clearance for AG-236 for polycythemia vera.
Tickers: $UE
Topics: commercialization strategy earnings report pipeline progress R&D expenses revenue growth